Table 5.
Motif in Reported I-Ag7 Binding Peptides
| Protein | Peptide | Method of Identification | Reference | Motif | ||||
|---|---|---|---|---|---|---|---|---|
| HEL (9–29) | AAAMKRHGLDNYRGYSLGNW | T cell hybridoma stimulation | 14 | + | ||||
| HEL (90–104) | SVNCAKKIVSDGNGM | T cell stimulation | 15 | + | ||||
| h/m GAD65 (524–543) | SRLSKVAPVIKARMMEYGTT | ′′ ′′ | 16 | + | ||||
| h GAD65 (509–528) | IPPSLRYLLDNEERMSRLSK | ′′ ′′ | 17 | + | ||||
| h GAD65 (247–266) | NMYAMMIAR FKMFPEVKEKG | ′′ ′′ | ′′ | + | ||||
| OVA (323–339) | ISQAVHAAHAEINEAGR | ′′ ′′ | 18 | − | ||||
| λ Repressor protein (12–26) | LEDARRLKAIYEKKK | ′′ ′′ | ′′ | + | ||||
| In serum albumin (560–574) | KPKATAEQLKTVMDD | Elution and sequencing | 7 | − | ||||
| Transferrin (55–68) | GHNYVTAIRNQQEG | ′′ ′′ | ′′ | + | ||||
| hRNPA1 (44–59) | VVMRDPQTKRSRGFGF | ′′ ′′ | ′′ | + | ||||
| hRNPA24B1 (51–66) | VVMRDPASKRSRGFGF | ′′ ′′ | ′′ | + | ||||
| hRNPA24B1 (31–43) | ETTeESLRNYYEQ | ′′ ′′ | ′′ | + | ||||
| r MOG (8–22) | PGYPIRALVGDEQED | Induction of CR-EAE | 9 | + | ||||
| m PLP (56–70) | DYEYLINVIHAFQYV | ′′ ′′ | ′′ | + | ||||
| m MBP (12–35) | YLATASTMDHARHGFLPRHRDTGI | ′′ ′′ | ′′ | + | ||||
| Heat shock protein (437–460) | VLGGGCALLRCIPALDSLTPANED | T cell hybridoma stimulation | 8 | + | ||||
| Carboxypeptidase H (362–382) | KNSLINYLEQIHRGVKGFVR | ′′ ′′ | ′′ | + | ||||
| Carboxypeptidase H (440–464) | FSPAVGVDFELESFSERKEEEKEEL | ′′ ′′ | ′′ | + | ||||
| Staphylococcal nuclease (61–79) | FTKKMVENAKKIEVEFDK | T cell immunogen and/or T cell | 19 | + | ||||
| Equine myoglobin (131–153) | MTKALELFRNDIAAKYKELGFQG | Hybridoma competition | ||||||
| m α-1 antitrypsin (148–163) | LSQAVHKAVLTIDETG | ′′ ′′ | ′′ | + | ||||
| m laminin b1 chain precursor (1594-1612) | MVKEALEEAEKAQVAAEKA | ′′ ′′ | ′′ | − | ||||
| m prostate secretory glycoprotein precursor (63–76) | FENRKRIEPVLIRK | ′′ ′′ | ′′ | + | ||||
| m myoglobin (131–153) | MSKALELFRNDIAAKYKLGFQG | ′′ ′′ | ′′ | + | ||||
| m insulin B chain (9–23) | SHLVEALYLVCGERG | T cell stimulation | 20 | + | ||||
| m TCR Vβ8.2 (38–60) | DTGHGLRLIH YSYGAGSTEKGDI | ′′ ′′ | 21 | + | ||||
| m TCR Vβ6 (38–60) | DSGKGLRLIYYSITENDLQKGDL | ′′ ′′ | ′′ | + | ||||
| m myoglobin (110–121) | IIIEVLKKRHSG | ′′ ′′ | ′′ | + | ||||
| m myoglobin (69–78) | LTALGT ILKK | ′′ ′′ | ′′ | + | ||||
| Ribosomal S30 peptide (75–96) | KVHGSLARAGKVRGQTPKVAKQ | ′′ ′′ | ′′ | + | ||||
| m MOG (35–55) | MEVGWYRSPFSRVVH LVR NGK | Induction of CR-EAE | 22 | + |
Residues shown to be well tolerated at the p6 or p9 anchor positions (see Table 4) are bolded; weakly tolerated are underlined; nontolerated are bolded in lower case. h, human; m, mouse; r, rat.